|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
APRIL 2, 2007
Advanced Life Sciences Is Advancing On Anthrax  Investors who stuck with Advanced Life Sciences (ADLS
) even after it delayed completion of Phase 3 clinical trials on cethromycin felt rewarded when the Food & Drug Administration granted it "Orphan Drug" designation. Such status is given to drugs that offer potential therapeutic value in treating rare diseases--those affecting fewer than 200,000 Americans--and grants it seven years of market exclusivity once approved. Cethromycin is a treatment for anthrax and "community acquired pneumonia." Some analysts also stayed bullish despite the three-month delay. President John Flavin says the results will now be out in the second quarter. The delay was disappointing because it pushed back the filing for a new drug application, "but it's a prudent approach" to get the best study and results possible, says Angela Larson of Susquehanna Financial Group, who is "positive" on the stock. The trials started in December with 1,000 patients in 16 countries. The U.S. Army Medical Research Institute of Infectious Diseases is collaborating with Advanced Life on cethromycin. Ilya Kravets of Rodman & Renshaw rates the stock, now at 2.40, "outperform," with a 12-month target of 5.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2007, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version